Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Receivables - Net: 2023-2024

  • Artiva Biotherapeutics' Receivables - Net was N/A to $569,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $569,000, marking a year-over-year change of. This contributed to the annual value of $1.0 million for FY2023, which is N/A change from last year.
  • Per Artiva Biotherapeutics' latest filing, its Receivables - Net stood at $569,000 for Q3 2024, which was down 0.00% from $569,000 recorded in Q2 2024.
  • In the past 5 years, Artiva Biotherapeutics' Receivables - Net registered a high of $1.0 million during Q4 2023, and its lowest value of $569,000 during Q2 2024.
  • Its 2-year average for Receivables - Net is $724,000, with a median of $569,000 in 2024.